Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.
Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G Jr, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Judd J, et al. Among authors: spira ai. Mol Cancer Ther. 2021 Dec;20(12):2577-2584. doi: 10.1158/1535-7163.MCT-21-0201. Epub 2021 Sep 13. Mol Cancer Ther. 2021. PMID: 34518295 Free PMC article.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Butts C, et al. Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. Lancet Oncol. 2014. PMID: 24331154 Free article. Clinical Trial.
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Thatcher N, et al. Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1. Lancet Oncol. 2015. PMID: 26045340 Free article. Clinical Trial.
Prospects and progress of atezolizumab in non-small cell lung cancer.
Vansteenkiste J, Wauters E, Park K, Rittmeyer A, Sandler A, Spira A. Vansteenkiste J, et al. Expert Opin Biol Ther. 2017 Jun;17(6):781-789. doi: 10.1080/14712598.2017.1309389. Epub 2017 Mar 28. Expert Opin Biol Ther. 2017. PMID: 28335643 Review.
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Peters S, et al. N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6. N Engl J Med. 2017. PMID: 28586279 Free article. Clinical Trial.
Efficacy and Safety Results of the Afatinib Expanded Access Program.
Kim ES, Halmos B, Kohut IF, Patel T, Rostorfer RD, Spira AI, Cseh A, McKay J, Wallenstein G, Mileham KF. Kim ES, et al. Among authors: spira ai. Oncol Ther. 2017;5(1):103-110. doi: 10.1007/s40487-017-0043-5. Epub 2017 Apr 10. Oncol Ther. 2017. PMID: 28680960 Free PMC article.
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.
Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR. Yu HA, et al. Clin Cancer Res. 2017 Dec 15;23(24):7467-7473. doi: 10.1158/1078-0432.CCR-17-1447. Epub 2017 Sep 27. Clin Cancer Res. 2017. PMID: 28954786 Free PMC article. Clinical Trial.
Product review on the Anti-PD-L1 antibody atezolizumab.
Shah NJ, Kelly WJ, Liu SV, Choquette K, Spira A. Shah NJ, et al. Hum Vaccin Immunother. 2018 Feb 1;14(2):269-276. doi: 10.1080/21645515.2017.1403694. Epub 2017 Dec 20. Hum Vaccin Immunother. 2018. PMID: 29194007 Free PMC article.
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Socinski MA, et al. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863955 Free article. Clinical Trial.
143 results